FLT3 and acute myeloid leukemia: Previously, we have developed a novel ADC, ASP1235 which was originally named AGS62P1, targeting Fms-like tyrosine kinase 3 (FLT3) which is overexpressed on the leukemic blasts in over 90% of AML patients [12, 13].